Neurocrine Biosciences (Nasdaq: NBIX)has agreed to acquire Redwood City, California-based Soleno Therapeutics (Nasdaq: SLNO) for $2.9 billion in cash.
Why it's the BFD: This would give Neurocrine its first metabolic disease drug — something that's evolved from "nice to have" to "must have" in the GLP-1 era.
For the first time, Medicare is covering some cannabis products under a pilot program that opens up more of the nearly $30 billion hemp industry to seniors.
Why it matters: The effort is part of a White House push to reschedule marijuana and tracks with Health Secretary Robert F. Kennedy Jr.'s interest in non-pharmaceutical, alternative treatments.
Democrats weighing runs for the White House want to forget many of the positions they took in 2020 — and they're hoping voters will too.
Why it matters: Leaders and would-be leaders in the party have shifted their views on border security, DEI, crime, climate change, COVID-era lockdowns and more — all with an eye on this year's midterms and the 2028 presidential election.
Phone-free bars and restaurants are emerging across the U.S. as people seek to disconnect from screens and devices.
The big picture: This trend is emerging amid a societal shift, with several countries imposing social media bans for children and teens, some U.S. states prohibiting phone use at school, and more live events restricting phones.
